Kyverna Therapeutics, Inc.KYTX

Kyverna Therapeutics burned $39.7 million in net loss during the quarter to March 2026 and booked zero revenue, a maths problem that even the most upbeat CAR T-cell slide deck struggles to spin. The company’s cash pile stood at $32.2 million on 31 March 2026, against liabilities of $61.4 million, leaving shareholders’ equity at $195.6 million but with the operating cash burn accelerating to $41.6 million in the period. The platform promises a next-generation shift in autoimmune therapy, but the balance sheet is still writing red ink. (source: Kyverna Therapeutics, Inc. 10-Q for the quarter ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1994702/000119312526248435/xslF345X06/ownership.xml)

Kyverna’s science is not in doubt: it is running clinical trials for B-cell targeting CAR T-cell therapies KYV-101 and KYV-201 aimed at autoimmune diseases. Participation in these trials is currently the only route for patients to access the investigational products, a reminder that the company is still in the evidence-building phase rather than the revenue phase. The firm bills itself as a patient-centred, clinical-stage biotech focused on cell therapies for autoimmune diseases, but the only clinical activity that converts to cash today is the one that happens inside its bank statements. (source: Kyverna product rail, https://kyvernatx.com/platform-pipeline/clinical-trials/)

On the financing side, Kyverna’s loan facility now embeds minimum revenue covenants effective from the quarter ending 30 June 2027, with exceptions tied to cash and market capitalisation. In plain language, if the share price stays weak and the cash runway shortens, the bank gets to lean on the covenant lever rather than the science lever. The company’s dilution track is already visible: diluted weighted average shares outstanding reached 60.4 million for the quarter, while diluted loss per share was 66 cents. R&D expense clocked $30.1 million in the same period, underscoring that the business is spending to build data, not to book sales. (source: Kyverna Therapeutics, Inc. 10-Q for the quarter ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1994702/000119312526248435/xslF345X06/ownership.xml; KYTX 8-K dated 2026-07-09, https://www.sec.gov/Archives/edgar/data/1994702/000119312526298979/kytx-20260708.htm)

The company’s pipeline page shows a B-cell targeting pipeline designed to address autoimmune diseases, but the SEC filings do not supply a revenue line, an approval, or a launch date. The visuals-pipeline graphics and team photos-are aspirational marketing rather than audited financials. The same holds for the treatment platform pages for KYV-101 and KYV-201; they describe next-generation CAR T-cell therapy under development but do not include any sales, patient numbers, or payer contracts. (source: Kyverna product rails, https://kyvernatx.com/platform-pipeline/ and https://kyvernatx.com/platform-pipeline/pipeline/)

Kyverna’s most recent SEC filings do not report capex beyond a $5,000 line in the 10-K for the year ended 31 December 2025, a figure so small it reinforces the pre-revenue, pre-commercial status of the business. The company’s property, plant, and equipment additions are immaterial while the cash burn remains material, a mismatch that keeps the spotlight on financing and milestones rather than on factories or fleets. (source: Kyverna Therapeutics, Inc. 10-K for the year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1994702/000119312526288986/kytx-20260311.htm)

If you want a visual of the pipeline, Kyverna provides a chart on its site, but the chart is a slide, not a bank statement. The same source rails that trumpet the clinical pipeline do not disclose any data on patient enrolment, trial sites, or regulatory interactions beyond the generic statement that participation in clinical trials is the best route to access the investigational products. (source: Kyverna pipeline chart, https://kyverna.wpenginepowered.com/wp-content/uploads/2026/04/Pipeline_per_S_1_20260401_2026_Priorities-scaled.png)

The company’s investor materials are heavy on platform graphics and light on cash metrics. For readers who prefer evidence over enthusiasm, the quarterly 10-Q and related 8-K filings remain the only primary documents that matter until the revenue dial turns from zero to something else. (source: Kyverna Therapeutics, Inc. SEC EDGAR filing index for CIK 1994702, https://www.sec.gov/edgar/browse/?CIK=1994702)